Approval · Notice of Compliance 34501 · 2024
TAFINLAR: Notice of Compliance 34501
Issued December 5, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34501
- Date
- December 5, 2024
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TAFINLAR | Not yet assigned | — |
Medicinal ingredients
- DABRAFENIB MESYLATE 50 MG per CAP
- DABRAFENIB MESYLATE 75 MG per CAP
- DABRAFENIB MESYLATE 10 MG per TAB